Does Cosentyx (secukinumab) reduce how well vaccines work?
Cosentyx (secukinumab) is an IL-17A inhibitor used for autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. By blocking IL-17A signaling, it can change immune responses to infections and immune stimulation in general, which is why clinicians pay close attention to vaccination timing and vaccine type. However, the provided information does not include specific evidence on whether Cosentyx reduces vaccine effectiveness for particular vaccines.
Which vaccines are different for people on Cosentyx?
A key practical distinction is that some biologic therapies limit use of live vaccines, while inactivated (non-live) vaccines are generally preferred. The provided information does not specify Cosentyx’s exact vaccine recommendations (for example, which vaccines are considered live vs. non-live in a given guideline).
Should patients get vaccines before starting Cosentyx?
In practice, many immunology/biologic treatment plans try to:
- update vaccinations before starting therapy when possible, and
- time vaccines around treatment start dates.
But the information provided here does not include Cosentyx-specific timing guidance.
What do patients usually ask about with vaccine responses on Cosentyx?
Common questions include whether vaccine protection (for influenza, COVID-19, pneumococcal, shingles, etc.) is weaker on IL-17 inhibitors and whether booster doses are needed. This answer cannot confirm those specifics without the missing Cosentyx vaccine-response data.
If you tell me your vaccines, I can tailor the answer
If you share which vaccine you mean (for example, flu shot, COVID-19, shingles, pneumococcal) and whether you’ve already started Cosentyx, I can explain the typical considerations (live vs. inactivated, timing, and what clinicians look for)—but I need the referenced guideline or study information to be accurate.
Sources
None provided in the prompt.